Iqmike, I have no idea where TRVN will trade at on Monday. I do think a market cap of $2 billion for a company with a medication that is said to have a $1.5 billion target market is not to far out there. Given that Pfizer makes it for TRVN would make them a logical candidate to acquire it. Why not move on it sooner before the market begins to figure out how undervalued this company is. (Makes me wonder which stock would have the best percentage gain in a takeover from here...AMRN? or TRVN? I hate to say it but TRVN would likely win in that regard. Both are similar...TRVN must either JV or GIA in the US...unless a BO first. AMRN may have to either get JV partner(s) for Europe or (hopefully) sell the company.